Compared with NSCLC, colorectal cancers (CRCs) associated with the KRAS G12C mutation are much less responsive to sotorasib and other KRAS G12C inhibitors in clinical trials47. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.